variant_id	variant_civic_url	gene	entrez_id	variant	summary	variant_groups	chromosome	start	stop	reference_bases	variant_bases	representative_transcript	ensembl_version	reference_build	chromosome2	start2	stop2	representative_transcript2
1	https://civic.genome.wustl.edu/#/events/genes/4/summary/variants/1/summary#variant	ABL1	25	BCR-ABL	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response.		22	23522397	23632600			ENST00000305877.8	75	GRCh37	9	133729451	133763063	ENST00000318560.5
2	https://civic.genome.wustl.edu/#/events/genes/4/summary/variants/2/summary#variant	ABL1	25	BCR-ABL T334I	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Imatinib Resistance,Imatinib Resistance	9	133748283	133748283	C	T	ENST00000372348.2	75	GRCh37				
3	https://civic.genome.wustl.edu/#/events/genes/4/summary/variants/3/summary#variant	ABL1	25	BCR-ABL E255K	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Imatinib Resistance	9	133738363	133738363	G	A	ENST00000318560.5	75	GRCh37				
4	https://civic.genome.wustl.edu/#/events/genes/2/summary/variants/4/summary#variant	AKT1	207	E17K	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.		14	105246551	105246551	C	T	ENST00000407796.2	75	GRCh37				
5	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/5/summary#variant	ALK	238	EML4-ALK	The EML4-ALK fusion has been seen in non-small cell lung cancer and appears to be an alternative mechanism for ALK activation. Cells with this fusion have been shown to be sensitive to the ALK inhibitor crizotinib.	ALK Fusions	2	42396490	42522656			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3
6	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/6/summary#variant	ALK	238	EML4-ALK C1156Y	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this mutation has been shown to confer resistance to crizotinib.	ALK Fusions,Crizotinib Resistance	2	29445258	29445258	C	T	ENST00000389048.3	75	GRCh37				
7	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/7/summary#variant	ALK	238	EML4-ALK L1196M	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this mutation has been shown to confer resistance to crizotinib.	ALK Fusions,Crizotinib Resistance	2	29443631	29443631	G	T	ENST00000389048.3	75	GRCh37				
8	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/8/summary#variant	ALK	238	F1174L	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Crizotinib Resistance	2	29443695	29443695	G	T	ENST00000389048.3	75	GRCh37				
9	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/9/summary#variant	ALK	238	R1275Q	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.		2	29432664	29432664	C	T	ENST00000389048.3	75	GRCh37				
10	https://civic.genome.wustl.edu/#/events/genes/3/summary/variants/10/summary#variant	ARAF	369	S214C	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.		X	47426121	47426121	C	G	ENST00000377045.4	75	GRCh37				
11	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/11/summary#variant	BRAF	673	V600D	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Other V600's	7	140453135	140453136	CA	AT	ENST00000288602.6	75	GRCh37				
12	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/12/summary#variant	BRAF	673	V600E	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.		7	140453136	140453136	A	T	ENST00000288602.6	75	GRCh37				
13	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/13/summary#variant	BRAF	673	V600E+V600M	A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.	Other V600's	7	140453135	140453137			ENST00000288602.6	75	GRCh37				
14	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/14/summary#variant	BRAF	673	V600E AMPLIFICATION	Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry.		7	140434279	140624564			ENST00000288602.6	75	GRCh37				
17	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/17/summary#variant	BRAF	673	V600	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutation pages on the left sidebar.		7	140453136	140453137			ENST00000288602.6	75	GRCh37				
18	https://civic.genome.wustl.edu/#/events/genes/8/summary/variants/18/summary#variant	CCND1	595	AMPLIFICATION	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.		11	69455855	69469242			ENST00000227507.2	75	GRCh37				
19	https://civic.genome.wustl.edu/#/events/genes/8/summary/variants/19/summary#variant	CCND1	595	EXPRESSION	CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.		11	69455855	69469242			ENST00000227507.2	75	GRCh37				
20	https://civic.genome.wustl.edu/#/events/genes/8/summary/variants/20/summary#variant	CCND1	595	OVEREXPRESSION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		11	69455855	69469242			ENST00000227507.2	75	GRCh37				
21	https://civic.genome.wustl.edu/#/events/genes/9/summary/variants/21/summary#variant	CCND2	894	OVEREXPRESSION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		12	4382938	4414516			ENST00000261254.3	75	GRCh37				
22	https://civic.genome.wustl.edu/#/events/genes/9/summary/variants/22/summary#variant	CCND2	894	PROMOTER DEMETHYLATION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		12	4381437	4382937			ENST00000261254.3	75	GRCh37				
23	https://civic.genome.wustl.edu/#/events/genes/10/summary/variants/23/summary#variant	CCND3	896	LOSS	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.		6	41902671	41909586			ENST00000372991.4	75	GRCh37				
24	https://civic.genome.wustl.edu/#/events/genes/11/summary/variants/24/summary#variant	CCNE1	898	OVEREXPRESSION	Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.		19	30302805	30315215			ENST00000262643.3	75	GRCh37				
25	https://civic.genome.wustl.edu/#/events/genes/13/summary/variants/25/summary#variant	CDK4	1019	EXPRESSION	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.		12	58141510	58146304			ENST00000257904.6	75	GRCh37				
27	https://civic.genome.wustl.edu/#/events/genes/14/summary/variants/27/summary#variant	CDKN2A	1029	PROMOTER HYPERMETHYLATION	CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.		9	21974827	21994591			ENST00000498124.1	75	GRCh37				
28	https://civic.genome.wustl.edu/#/events/genes/15/summary/variants/28/summary#variant	CEBPA	1050	N-TERMINAL FRAME SHIFT	CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity.		19	33792961	33793470			ENST00000498907.2	75	GRCh37				
29	https://civic.genome.wustl.edu/#/events/genes/15/summary/variants/29/summary#variant	CEBPA	1050	MUTATION	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.		19	33790840	33793470			ENST00000498907.2	75	GRCh37				
30	https://civic.genome.wustl.edu/#/events/genes/33/summary/variants/30/summary#variant	CSF1R	1436	MEF2D-CSF1R	MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.		1	156446804	156470620			ENST00000348159.4	75	GRCh37	5	149433787	149441412	
31	https://civic.genome.wustl.edu/#/events/genes/17/summary/variants/31/summary#variant	PRKACA	5566	DNAJB1-PRKACA	This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.		19	14628951	14629232			ENST00000254322.2	75	GRCh37	19	14202500	14218221	ENST00000308677.4
32	https://civic.genome.wustl.edu/#/events/genes/18/summary/variants/32/summary#variant	DNMT3A	1788	R882	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.		2	25457241	25457243			ENST00000264709.3	75	GRCh37				
33	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/33/summary#variant	EGFR	1956	L858R	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.		7	55259514	55259515	CT	AG	ENST00000275493.2	75	GRCh37				
34	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/34/summary#variant	EGFR	1956	T790M	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. The third generation TKI's are being developed with this resistance problem in mind, and early stage experiments have shown some efficacy of these drugs in previously resistant tumors with mutant EGFR.	EGFR TKI Resistance,EGFR TKI Resistance	7	55249071	55249071	C	T	ENST00000275493.2	75	GRCh37				
35	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/35/summary#variant	ERBB2	2064	D769H	ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37880261	37880261	G	C	ENST00000269571.5	75	GRCh37				
36	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/36/summary#variant	ERBB2	2064	D769Y	ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37880261	37880261	G	T	ENST00000269571.5	75	GRCh37				
37	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/37/summary#variant	ERBB2	2064	DEL 755-759	ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37880219	37880233	TTGAGGGAAAACACA		ENST00000269571.5	75	GRCh37				
38	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/38/summary#variant	ERBB2	2064	G309A	ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37868205	37868205	G	C	ENST00000269571.5	75	GRCh37				
39	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/39/summary#variant	ERBB2	2064	L755S	ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.		17	37880220	37880220	T	C	ENST00000269571.5	75	GRCh37				
40	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/40/summary#variant	ERBB2	2064	L755W	ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37880220	37880220	T	G	ENST00000269571.5	75	GRCh37				
41	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/41/summary#variant	ERBB2	2064	P780INS	ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881011	37881012	-	GGCTCCCCA	ENST00000269571.5	75	GRCh37				
42	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/42/summary#variant	ERBB2	2064	R678Q	ERBB2 R678Q was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37879658	37879658	G	A	ENST00000269571.5	75	GRCh37				
43	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/43/summary#variant	ERBB2	2064	R896C	ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881616	37881616	C	T	ENST00000269571.5	75	GRCh37				
44	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/44/summary#variant	ERBB2	2064	V777L	ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881000	37881000	G	T	ENST00000269571.5	75	GRCh37				
45	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/45/summary#variant	ERBB2	2064	V842I	ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881332	37881332	G	A	ENST00000269571.5	75	GRCh37				
46	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/46/summary#variant	ESR1	2099	L536Q	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419920	152419921	TC	AG	ENST00000440973.1	75	GRCh37				
47	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/47/summary#variant	ESR1	2099	D538G	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419926	152419926	A	G	ENST00000206249.3	75	GRCh37				
48	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/48/summary#variant	ESR1	2099	Y537C	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419923	152419923	A	G	ENST00000206249.3	75	GRCh37				
49	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/49/summary#variant	ESR1	2099	Y537N	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419922	152419922	T	A	ENST00000206249.3	75	GRCh37				
50	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/50/summary#variant	ESR1	2099	Y537S	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419923	152419923	A	C	ENST00000206249.3	75	GRCh37				
52	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/52/summary#variant	FGFR2	2263	FGFR2-MGEA5	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	10	123239535	123357598			ENST00000358487.5	75	GRCh37	10	103544209	103552700	ENST00000361464.3
53	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/53/summary#variant	FGFR3	2261	FGFR3-BAIAP2L1	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	4	1795039	1810599			ENST00000340107.4	75	GRCh37	7	97991744	97920963	
54	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/54/summary#variant	FGFR3	2261	FGFR2-TACC3	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	4	123243212	123357598			ENST00000358487.5	75	GRCh37	4	1723266	1741505	
55	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/55/summary#variant	FLT3	2322	ITD MUTATION	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.		13	28608219	28608351			ENST00000241453.7	75	GRCh37				
56	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/56/summary#variant	FLT3	2322	TKD MUTATION	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.		13	28592642	28592642	C	A	ENST00000241453.7	75	GRCh37				
57	https://civic.genome.wustl.edu/#/events/genes/25/summary/variants/57/summary#variant	GATA2	2624	EXPRESSION	GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer.		3	128198270	128212028			ENST00000341105.2	75	GRCh37				
58	https://civic.genome.wustl.edu/#/events/genes/26/summary/variants/58/summary#variant	IDH1	3417	R132	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113111	209113113			ENST00000415913.1	75	GRCh37				
59	https://civic.genome.wustl.edu/#/events/genes/26/summary/variants/59/summary#variant	IDH1	3417	R132C	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113113	209113113	G	A	ENST00000415913.1	75	GRCh37				
62	https://civic.genome.wustl.edu/#/events/genes/27/summary/variants/62/summary#variant	IDH2	3418	R140Q/L	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140Q/L mutants have shown improved overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.		15	90631934	90631934	C	T / A	ENST00000330062.3	75	GRCh37				
63	https://civic.genome.wustl.edu/#/events/genes/27/summary/variants/63/summary#variant	IDH2	3418	R172K	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.		15	90631838	90631838	C	T	ENST00000330062.3	75	GRCh37				
64	https://civic.genome.wustl.edu/#/events/genes/28/summary/variants/64/summary#variant	JAK2	3717	V617F	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases, occuring in around half of all MPD's. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.		9	5073770	5073770	G	T	ENST00000381652.3	75	GRCh37				
65	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/65/summary#variant	KIT	3815	D816V	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	KIT Exon 17	4	55599321	55599321	A	T	ENST00000288135.5	75	GRCh37				
66	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/66/summary#variant	KIT	3815	EXON 11 MUTATION	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.	KIT Exon 11,KIT Exon 11,KIT Exon 11,KIT Exon 11,KIT Exon 11,KIT Exon 11	4	55593582	55593708			ENST00000288135.5	75	GRCh37				
67	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/67/summary#variant	KIT	3815	INTERNAL DUPLICATION	c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.	KIT Exon 11	4	55593582	55593708			ENST00000288135.5	75	GRCh37				
69	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/69/summary#variant	KIT	3815	EXON 14 MUTATION	c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.		4	55595501	55595651			ENST00000288135.5	75	GRCh37				
72	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/72/summary#variant	KIT	3815	L576P	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	KIT Exon 11,KIT Exon 11,KIT Exon 11	4	55593661	55593661	T	C	ENST00000288135.5	75	GRCh37				
73	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/73/summary#variant	KIT	3815	V654A	KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.	KIT Exon 11,KIT Exon 11	4	55594258	55594258	T	C	ENST00000288135.5	75	GRCh37				
75	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/75/summary#variant	KRAS	3845	EXON 2 MUTATION	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.		12	25398208	25398329			ENST00000256078.4	75	GRCh37				
76	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/76/summary#variant	KRAS	3845	G12	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.		12	25398284	25398285			ENST00000256078.4	75	GRCh37				
77	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/77/summary#variant	KRAS	3845	G12/G13	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.		12	25398280	25398285			ENST00000256078.4	75	GRCh37				
78	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/78/summary#variant	KRAS	3845	G12C	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.	EGFR TKI Resistance	12	25398285	25398285	C	A	ENST00000256078.4	75	GRCh37				
79	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/79/summary#variant	KRAS	3845	G12D	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.	EGFR TKI Resistance	12	25398284	25398284	C	T	ENST00000256078.4	75	GRCh37				
80	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/80/summary#variant	KRAS	3845	G13	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.		12	25398281	25398282			ENST00000256078.4	75	GRCh37				
81	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/81/summary#variant	KRAS	3845	G13D	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al.) could not reproduce this finding and another prospective phase II trial is currently ongoing.		12	25398281	25398281	C	T	ENST00000256078.4	75	GRCh37				
82	https://civic.genome.wustl.edu/#/events/genes/31/summary/variants/82/summary#variant	MAP2K1	5604	P124S	MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.		15	66729162	66729162	C	T	ENST00000307102.5	75	GRCh37				
83	https://civic.genome.wustl.edu/#/events/genes/31/summary/variants/83/summary#variant	MAP2K1	5604	Q56P	MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.		15	66727451	66727451	A	C	ENST00000307102.5	75	GRCh37				
85	https://civic.genome.wustl.edu/#/events/genes/34/summary/variants/85/summary#variant	MGMT	4255	PROMOTER METHYLATION	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.		10	131264495	131265656			ENST00000306010.7	75	GRCh37				
86	https://civic.genome.wustl.edu/#/events/genes/35/summary/variants/86/summary#variant	NPM1	4869	EXON 12 MUTATION	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.		5	170837531	170837569			ENST00000517671.1	75	GRCh37				
87	https://civic.genome.wustl.edu/#/events/genes/35/summary/variants/87/summary#variant	NPM1	4869	W288FS	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	NPM1 Exon 12,NPM1 Exon 12,NPM1 Exon 12,NPM1 Exon 12	5	170837546	170837547	-	TCAG	ENST00000517671.1	75	GRCh37				
88	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/88/summary#variant	NRAS	4893	EXON 2-3 MUTATION	NRAS exon 2 and 3 mutations were studied by Jakob et al in 2012 and were shown to be correlated with poorer overall survival relative to wild-type NRAS in melanoma patients.		1	115256421	115258798			ENST00000369535.4	75	GRCh37				
92	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/92/summary#variant	NRAS	4893	G12	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.		1	115258747	115258748			ENST00000369535.4	75	GRCh37				
93	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/93/summary#variant	NRAS	4893	G13D	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.		1	115258744	115258744	C	T	ENST00000369535.4	75	GRCh37				
94	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/94/summary#variant	NRAS	4893	Q61	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256528	115256530			ENST00000369535.4	75	GRCh37				
95	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/95/summary#variant	NRAS	4893	Q61L	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256529	115256529	T	A	ENST00000369535.4	75	GRCh37				
96	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/96/summary#variant	NRAS	4893	Q61R	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256529	115256529	T	C	ENST00000369535.4	75	GRCh37				
98	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/98/summary#variant	PDGFRA	5156	D842I	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152092	55152093	GA	AT	ENST00000257290.5	75	GRCh37				
99	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/99/summary#variant	PDGFRA	5156	D842V	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance,Imatinib Resistance,Imatinib Resistance,Imatinib Resistance	4	55152093	55152093	A	T	ENST00000257290.5	75	GRCh37				
100	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/100/summary#variant	PDGFRA	5156	D842Y	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152092	55152092	G	T	ENST00000257290.5	75	GRCh37				
101	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/101/summary#variant	PDGFRA	5156	DEL I843	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152095	55152097	ATC		ENST00000257290.5	75	GRCh37				
102	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/102/summary#variant	PDGFRA	5156	DI842-843VM	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152093	55152097	ACATC	TCATG	ENST00000257290.5	75	GRCh37				
103	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/103/summary#variant	PIK3CA	5290	E542K	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with other PIK3CA variants or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178936082	178936082	G	A	ENST00000263967.3	75	GRCh37				
104	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/104/summary#variant	PIK3CA	5290	E545K	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178936091	178936091	G	A	ENST00000263967.3	75	GRCh37				
105	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/105/summary#variant	PIK3CA	5290	EXON 21 MUTATION	PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.		3	178951882	178952495			ENST00000263967.3	75	GRCh37				
106	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/106/summary#variant	PIK3CA	5290	EXON 10 MUTATION	PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178935998	178936122			ENST00000263967.3	75	GRCh37				
107	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/107/summary#variant	PIK3CA	5290	H1047R	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.		3	178952085	178952085	A	G	ENST00000263967.3	75	GRCh37				
108	https://civic.genome.wustl.edu/#/events/genes/39/summary/variants/108/summary#variant	PML	5371	PML-RARA	The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.		15	74287058	74325755			ENST00000268058.3	75	GRCh37	17	38504568	38513048	
110	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/110/summary#variant	PTEN	5728	R233*	PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.	PTEN Loss-of-Function,PTEN Loss-of-Function	10	89717672	89717672	C	T	ENST00000371953.3	75	GRCh37				
112	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/112/summary#variant	RET	5979	C634W	RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.	Motesanib Resistance	10	43609950	43609950	C	G	ENST00000355710.3	75	GRCh37				
113	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/113/summary#variant	RET	5979	M918T	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Motesanib Resistance	10	43617416	43617416	T	C	ENST00000355710.3	75	GRCh37				
114	https://civic.genome.wustl.edu/#/events/genes/44/summary/variants/114/summary#variant	SF3B1	23451	K666N	SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.		2	198267359	198267359	C	A	ENST00000335508.6	75	GRCh37				
116	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/116/summary#variant	TP53	7157	R175H	While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant.		17	7578406	7578406	C	T	ENST00000269305.4	75	GRCh37				
117	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/117/summary#variant	TP53	7157	R248Q	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.		17	7577538	7577538	C	T	ENST00000269305.4	75	GRCh37				
118	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/118/summary#variant	TP53	7157	R248W	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.		17	7577539	7577539	G	A	ENST00000269305.4	75	GRCh37				
119	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/119/summary#variant	TP53	7157	R249	This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577535	7577535	C	G	ENST00000269305.4	75	GRCh37				
121	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/121/summary#variant	TP53	7157	R273C	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577121	7577121	G	A	ENST00000269305.4	75	GRCh37				
122	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/122/summary#variant	TP53	7157	R273H	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577120	7577120	C	T	ENST00000269305.4	75	GRCh37				
124	https://civic.genome.wustl.edu/#/events/genes/46/summary/variants/124/summary#variant	TSC1	7248	FRAMESHIFT TRUNCATION	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	TSC Loss,TSC Loss								GRCh37				
125	https://civic.genome.wustl.edu/#/events/genes/46/summary/variants/125/summary#variant	TSC1	7248	LOSS-OF-FUNCTION	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	TSC Loss	9	135766735	135820008			ENST00000298552.3	75	GRCh37				
127	https://civic.genome.wustl.edu/#/events/genes/48/summary/variants/127/summary#variant	U2AF1	7307	Q157P/R	U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.		21	44514777	44514777	T	G	ENST00000291552.4	75	GRCh37				
128	https://civic.genome.wustl.edu/#/events/genes/48/summary/variants/128/summary#variant	U2AF1	7307	S34Y/F	U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.		21	44524456	44524456	G	A	ENST00000291552.4	75	GRCh37				
129	https://civic.genome.wustl.edu/#/events/genes/49/summary/variants/129/summary#variant	WT1	7490	EXON 7 MUTATION	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.		11	32417803	32417953			ENST00000332351.3	75	GRCh37				
130	https://civic.genome.wustl.edu/#/events/genes/49/summary/variants/130/summary#variant	WT1	7490	EXON 9 MUTATION	WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.		11	32413518	32413610			ENST00000332351.3	75	GRCh37				
131	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/131/summary#variant	BRCA1	672	LOSS-OF-FUNCTION	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	BRCA Germline Variants	17	41196312	41277387			ENST00000357654.3	75	GRCh37				
132	https://civic.genome.wustl.edu/#/events/genes/7/summary/variants/132/summary#variant	BRCA2	675	LOSS-OF-FUNCTION	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	BRCA Germline Variants	13	32889611	32973347			ENST00000380152.3	75	GRCh37				
133	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/133/summary#variant	EGFR	1956	EXON 19 DELETION	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.		7	55242415	55242513			ENST00000275493.2	75	GRCh37				
134	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/134/summary#variant	EGFR	1956	G719S	While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.		7	55241707	55241707	G	A	ENST00000275493.2	75	GRCh37				
135	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/135/summary#variant	NOTCH1	4851	D1642H	Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer.		9	139399219	139399219	C	G	ENST00000277541.6	75	GRCh37				
136	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/136/summary#variant	NOTCH1	4851	R2327W	Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer.		9	139391212	139391212	G	A	ENST00000277541.6	75	GRCh37				
137	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/137/summary#variant	NOTCH1	4851	V2444FS	Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer.		9	139390861	139390861	G	TGT	ENST00000277541.6	75	GRCh37				
138	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/138/summary#variant	NOTCH1	4851	S2275FS	Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer.									GRCh37				
139	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/139/summary#variant	DDR2	4921	L63V	Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.		1	162724415	162724415	C	G	ENST00000367922.3	75	GRCh37				
140	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/140/summary#variant	DDR2	4921	L239R	Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.		1	162729630	167729630	T	G	ENST00000367922.3	75	GRCh37				
141	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/141/summary#variant	DDR2	4921	G253C	Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.		1	162729671	162729671	G	T	ENST00000367922.3	75	GRCh37				
142	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/142/summary#variant	DDR2	4921	G505S	Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.		1	162741822	162741822	G	A	ENST00000367922.3	75	GRCh37				
143	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/143/summary#variant	DDR2	4921	I638F	DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.		1	162745497	162745497	A	T	ENST00000367922.3	75	GRCh37				
144	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/144/summary#variant	DDR2	4921	G774V	Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.		1	162748407	162748407	G	T	ENST00000367922.3	75	GRCh37				
145	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/145/summary#variant	DDR2	4921	S768R	Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines.		1	162748390	162748390	T	A	ENST00000367922.3	75	GRCh37				
148	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/148/summary#variant	KRAS	3845	G12A	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	EGFR TKI Resistance	12	25398284	25398284	C	G	ENST00000256078.4	75	GRCh37				
151	https://civic.genome.wustl.edu/#/events/genes/59/summary/variants/151/summary#variant	BCL2	596	IGH-BCL2	The typically reciprocal t(14;18)(q32;q21) translocation involves rearrangement between the immunoglobulin heavy chain locus on chromosome 14 and the 3' UTR of BCL2 on chromosome 18, leading to the overexpression of BCL2. This rearrangment is observed in >80% of patients with follicular lymphoma.		14	106032614	107288051				75	GRCh37	18	60794268	60987019	ENST00000333681.4
152	https://civic.genome.wustl.edu/#/events/genes/59/summary/variants/152/summary#variant	BCL2	596	EXPRESSION			18	60790579	60987361			ENST00000398117.1	75	GRCh37				
153	https://civic.genome.wustl.edu/#/events/genes/56/summary/variants/153/summary#variant	FOXP1	27086	AMPLIFICATION	Amplication in FOXP1 has been shown to be associated with the ABC subtype of DLBCL.		3	71003844	71633140			ENST00000318789.4	75	GRCh37				
154	https://civic.genome.wustl.edu/#/events/genes/57/summary/variants/154/summary#variant	REL	5966	AMPLIFICATION			2	61108709	61149800			ENST00000295025.8	75	GRCh37				
155	https://civic.genome.wustl.edu/#/events/genes/43/summary/variants/155/summary#variant	RUNX1	861	MUTATION			21	36160098	36421641			ENST00000300305.3	75	GRCh37				
156	https://civic.genome.wustl.edu/#/events/genes/60/summary/variants/156/summary#variant	IGF2	3481	OVEREXPRESSION			11	2150348	2170833			ENST00000300632.5	75	GRCh37				
157	https://civic.genome.wustl.edu/#/events/genes/55/summary/variants/157/summary#variant	TET2	54790	MUTATION			4	106067450	106200973			ENST00000513237.1	75	GRCh37				
158	https://civic.genome.wustl.edu/#/events/genes/61/summary/variants/158/summary#variant	AURKA	6790	EXPRESSION			20	54944446	54967393			ENST00000395913.3	75	GRCh37				
159	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/159/summary#variant	VHL	7428	LOSS-OF-FUNCTION			3	10182692	10193904			ENST00000256474.2	75	GRCh37				
160	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/160/summary#variant	VHL	7428	MUTATION			3	10182692	10193904			ENST00000256474.2	75	GRCh37				
161	https://civic.genome.wustl.edu/#/events/genes/62/summary/variants/161/summary#variant	PBRM1	55193	MUTATION			3	52581857	52719852			ENST00000394830.3	75	GRCh37				
163	https://civic.genome.wustl.edu/#/events/genes/63/summary/variants/163/summary#variant	EZH2	2146	MUTATION			7	148504477	148581370			ENST00000320356.2	75	GRCh37				
164	https://civic.genome.wustl.edu/#/events/genes/53/summary/variants/164/summary#variant	FLI1	2313	EWSR1-FLI1 Type 1			22	29664007	29683123			ENST00000397938.2	75	GRCh37	11	128675261	128683162	ENST00000527786.2
165	https://civic.genome.wustl.edu/#/events/genes/63/summary/variants/165/summary#variant	EZH2	2146	Y646	Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 [pmid:20081860]		7	148508726	148508728			ENST00000320356.2	75	GRCh37				
167	https://civic.genome.wustl.edu/#/events/genes/64/summary/variants/167/summary#variant	KMT2D	8085	LOSS-OF-FUNCTION			12	49412758	49449107			ENST00000301067.7	75	GRCh37				
168	https://civic.genome.wustl.edu/#/events/genes/65/summary/variants/168/summary#variant	BTK	695	C481S			X	100611165	100611165	A	T	ENST00000308731.7	75	GRCh37				
169	https://civic.genome.wustl.edu/#/events/genes/2/summary/variants/169/summary#variant	AKT1	207	Q79K			14	105243048	105243048	G	T	ENST00000407796.2	75	GRCh37				
170	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/170/summary#variant	ALK	238	EML4-ALK AMPLIFICATION			2	42396490	42528380			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3
171	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/171/summary#variant	ALK	238	EML4-ALK G1202R			2	29443613	29443613	C	T	ENST00000389048.3	75	GRCh37				
172	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/172/summary#variant	ALK	238	EML4-ALK S1206Y			2	29443600	29443600	G	T	ENST00000389048.3	75	GRCh37				
173	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/173/summary#variant	ALK	238	EML4-ALK T1151INST			2	29445271	29445272		CGT	ENST00000389048.3	75	GRCh37				
174	https://civic.genome.wustl.edu/#/events/genes/66/summary/variants/174/summary#variant	APC	324	MUTATION			5	112043218	112181936			ENST00000457016.1	75	GRCh37				
175	https://civic.genome.wustl.edu/#/events/genes/67/summary/variants/175/summary#variant	AR	367	F877L			X	66943549	66943549	T	C	ENST00000374690.3	75	GRCh37				
176	https://civic.genome.wustl.edu/#/events/genes/67/summary/variants/176/summary#variant	AR	367	W742			X	66937370	66937372			ENST00000374690.3	75	GRCh37				
177	https://civic.genome.wustl.edu/#/events/genes/68/summary/variants/177/summary#variant	ASXL1	171023	MUTATION			20	30946155	31027122			ENST00000375687.4	75	GRCh37				
178	https://civic.genome.wustl.edu/#/events/genes/69/summary/variants/178/summary#variant	ATM	472	MUTATION			11	108093559	108239826			ENST00000278616.4	75	GRCh37				
179	https://civic.genome.wustl.edu/#/events/genes/69/summary/variants/179/summary#variant	ATM	472	UNDEREXPRESSION			11	108093559	108239826			ENST00000278616.4	75	GRCh37				
180	https://civic.genome.wustl.edu/#/events/genes/61/summary/variants/180/summary#variant	AURKA	6790	AMPLIFICATION			20	54944446	54967393			ENST00000395913.3	75	GRCh37				
181	https://civic.genome.wustl.edu/#/events/genes/61/summary/variants/181/summary#variant	AURKA	6790	OVEREXPRESSION			20	54944446	54967393			ENST00000395913.3	75	GRCh37				
182	https://civic.genome.wustl.edu/#/events/genes/70/summary/variants/182/summary#variant	BAP1	8314	EXPRESSION			3	52435029	52444366			ENST00000460680.1	75	GRCh37				
183	https://civic.genome.wustl.edu/#/events/genes/70/summary/variants/183/summary#variant	BAP1	8314	MUTATION			3	52435029	52444366			ENST00000460680.1	75	GRCh37				
184	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/184/summary#variant	BRAF	673	AKAP9-BRAF			7	91570181	91625114			ENST00000356239.3	75	GRCh37	7	140434279	140487384	ENST00000288602.6
185	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/185/summary#variant	BRCA1	672	MUTATION			17	41196312	41277387			ENST00000357654.3	75	GRCh37				
186	https://civic.genome.wustl.edu/#/events/genes/7/summary/variants/186/summary#variant	BRCA2	675	MUTATION			13	32889611	32973347			ENST00000380152.3	75	GRCh37				
187	https://civic.genome.wustl.edu/#/events/genes/11/summary/variants/187/summary#variant	CCNE1	898	AMPLIFICATION			19	30302805	30315215			ENST00000262643.3	75	GRCh37				
189	https://civic.genome.wustl.edu/#/events/genes/18/summary/variants/189/summary#variant	DNMT3A	1788	MUTATION	DNMT3A mutations can lead to epigenetic modifications and can cause excessive hypermethylation of tumor suppressor genes resulting in increased tumor growth. Methyltransferase inhibitors including decitabine and azacitidine inhibit the activity of DNMT3A and will decrease DNA methylation and potentially restore regular transcriptional activity of tumor suppressor genes.		2	25455845	25565459			ENST00000264709.3	75	GRCh37				
190	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/190/summary#variant	EGFR	1956	AMPLIFICATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37				
191	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/191/summary#variant	EGFR	1956	COPY NUMBER VARIATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37				
193	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/193/summary#variant	EGFR	1956	OVEREXPRESSION			7	55086794	55279321			ENST00000275493.2	75	GRCh37				
194	https://civic.genome.wustl.edu/#/events/genes/71/summary/variants/194/summary#variant	ERG	2078	EWSR1-ERG	EWSR1-ERG is found in 5% of patients with Ewing Sarcoma and considered to be diagnostic of this disease, a small tumor more often found in bone, but less frequently in soft tissue. To better identify EWSR1-ERG in patients, conventional cytogenetics methods were analyzed: FISH and RT-PCR. Ultimately concluding that more than one method is needed to accurately diagnose patients due to the strengths and weaknesses of each individual method.		22	29664007	29683123			ENST00000397938.2	75	GRCh37	21	39751949	39755845	ENST00000398907.1
195	https://civic.genome.wustl.edu/#/events/genes/71/summary/variants/195/summary#variant	ERG	2078	TMPRSS2-ERG	TMPRSS2 fusions are prevalent in Prostate Cancer. TMPRSS2 fusion with ETS family members such as ERG are among the most common. Fusion of TMPRSS2 with ERG may result in overexpression of ERG driven by the TMPRSS2 androgen-responsive promoter elements. Due to the high prevalence of this fusion, it may have diagnostic utility for prostate cancer, especially ERG expression positive prostate cancer.		21	42879877	42879992			ENST00000398585.3	75	GRCh37	21	39751949	39817544	ENST00000398910.1
196	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/196/summary#variant	FGFR3	2261	Y375C			4	1806099	1806099	A	G	ENST00000340107.4	75	GRCh37				
197	https://civic.genome.wustl.edu/#/events/genes/53/summary/variants/197/summary#variant	FLI1	2313	EWSR1-FLI1			22	29664007	29683123			ENST00000397938.2	75	GRCh37	11	128651853	128683162	
198	https://civic.genome.wustl.edu/#/events/genes/72/summary/variants/198/summary#variant	FOXL2	668	C134W	The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.		3	138665163	138665163	G	C	ENST00000330315.3	75	GRCh37				
199	https://civic.genome.wustl.edu/#/events/genes/27/summary/variants/199/summary#variant	IDH2	3418	R172			15	90631837	90631839			ENST00000330062.3	75	GRCh37				
200	https://civic.genome.wustl.edu/#/events/genes/73/summary/variants/200/summary#variant	IKZF1	10320	DELETION			7	50344378	50472799			ENST00000331340.3	75	GRCh37				
201	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/201/summary#variant	KIT	3815	M541L			4	55593464	55593464	A	C	ENST00000288135.5	75	GRCh37				
202	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/202/summary#variant	KIT	3815	V560DEL			4	55593612	55593614	GTT		ENST00000288135.5	75	GRCh37				
203	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/203/summary#variant	KRAS	3845	Q61			12	25380275	25380277			ENST00000256078.4	75	GRCh37				
204	https://civic.genome.wustl.edu/#/events/genes/74/summary/variants/204/summary#variant	NCOA3	8202	AMPLIFICATION			20	46130646	46285621			ENST00000372004.3	75	GRCh37				
205	https://civic.genome.wustl.edu/#/events/genes/74/summary/variants/205/summary#variant	NCOA3	8202	OVEREXPRESSION			20	46130646	46285621			ENST00000372004.3	75	GRCh37				
206	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/206/summary#variant	NOTCH1	4851	MUTATION			9	139388896	139440314			ENST00000277541.6	75	GRCh37				
207	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/207/summary#variant	NOTCH1	4851	P2514FS	This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling.		9	139390649	139390650	AG		ENST00000277541.6	75	GRCh37				
208	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/208/summary#variant	NRAS	4893	MUTATION			1	115247090	115259515			ENST00000369535.4	75	GRCh37				
209	https://civic.genome.wustl.edu/#/events/genes/75/summary/variants/209/summary#variant	PAX8	7849	PAX8-PPARG			2	114036521	113992971			ENST00000429538.3	75	GRCh37	3	12329400	12475810	
210	https://civic.genome.wustl.edu/#/events/genes/76/summary/variants/210/summary#variant	PGR	5241	EXPRESSION			11	100900355	101001255			ENST00000325455.5	75	GRCh37				
212	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/212/summary#variant	PIK3CA	5290	AMPLIFICATION			3	178866311	178957881			ENST00000263967.3	75	GRCh37				
213	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/213/summary#variant	PTEN	5728	DELETION			10	89622870	89731687			ENST00000371953.3	75	GRCh37				
214	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/214/summary#variant	PTEN	5728	LOSS			10	89622870	89731687			ENST00000371953.3	75	GRCh37				
215	https://civic.genome.wustl.edu/#/events/genes/44/summary/variants/215/summary#variant	SF3B1	23451	MUTATION			2	198254508	198299815			ENST00000335508.6	75	GRCh37				
216	https://civic.genome.wustl.edu/#/events/genes/77/summary/variants/216/summary#variant	SMAD4	4089	MUTATION			18	48556583	48611409			ENST00000342988.3	75	GRCh37				
217	https://civic.genome.wustl.edu/#/events/genes/78/summary/variants/217/summary#variant	SMARCA4	6597	MUTATION			19	11071598	11172958			ENST00000358026.2	75	GRCh37				
218	https://civic.genome.wustl.edu/#/events/genes/78/summary/variants/218/summary#variant	SMARCA4	6597	INACTIVATING MUTATION			19	11071598	11172958			ENST00000358026.2	75	GRCh37				
219	https://civic.genome.wustl.edu/#/events/genes/79/summary/variants/219/summary#variant	TERT	7015	AMPLIFICATION			5	1253282	1295162			ENST00000310581.5	75	GRCh37				
220	https://civic.genome.wustl.edu/#/events/genes/79/summary/variants/220/summary#variant	TERT	7015	PROMOTER MUTATION			5	1295161	1295373			ENST00000310581.5	75	GRCh37				
221	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/221/summary#variant	TP53	7157	DELETERIOUS MUTATION			17	7571720	7590856			ENST00000269305.4	75	GRCh37				
222	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/222/summary#variant	TP53	7157	MUTATION			17	7571720	7590856			ENST00000269305.4	75	GRCh37				
223	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/223/summary#variant	TP53	7157	TRUNCATING MUTATION			17	7573998	7579714			ENST00000269305.4	75	GRCh37				
224	https://civic.genome.wustl.edu/#/events/genes/80/summary/variants/224/summary#variant	TTF1	7270	AMPLIFICATION			9	135251008	135282209			ENST00000334270.2	75	GRCh37				
230	https://civic.genome.wustl.edu/#/events/genes/8950/summary/variants/230/summary#variant	CHEK2	11200	LOSS-OF-FUNCTION			22	29083732	29137832			ENST00000328354.6	75	GRCh37				
232	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/232/summary#variant	ERBB2	2064	OVEREXPRESSION			17	37844167	37884614			ENST00000584601.1	75	GRCh37				
236	https://civic.genome.wustl.edu/#/events/genes/12112/summary/variants/236/summary#variant	CDK12	51755	LOSS-OF-FUNCTION			17	37618292	37691399			ENST00000447079.4	75	GRCh37				
238	https://civic.genome.wustl.edu/#/events/genes/9189/summary/variants/238/summary#variant	NT5C2	22978	R367Q			10	104852955	104852955	C	T	ENST00000343289.5	75	GRCh37				
239	https://civic.genome.wustl.edu/#/events/genes/9189/summary/variants/239/summary#variant	NT5C2	22978	K359Q			10	104852980	104852980	T	G	ENST00000343289.5	75	GRCh37				
240	https://civic.genome.wustl.edu/#/events/genes/9189/summary/variants/240/summary#variant	NT5C2	22978	D407A			10	104850745	104850745	T	G	ENST00000343289.5	75	GRCh37				
241	https://civic.genome.wustl.edu/#/events/genes/4/summary/variants/241/summary#variant	ABL1	25	BCR-ABL F317L	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Imatinib Resistance	9	133748288	133748288	T	C	ENST00000318560.5	75	GRCh37				
242	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/242/summary#variant	TP53	7157	DNA BINDING DOMAIN MUTATION			17	7577149	7578443			ENST00000269305.4	75	GRCh37				
243	https://civic.genome.wustl.edu/#/events/genes/69/summary/variants/243/summary#variant	ATM	472	V2288fs*1	A frameshift mutation predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain.		11	108196840	108196841	TC	-	ENST00000278616.4	75	GRCh37				
244	https://civic.genome.wustl.edu/#/events/genes/69/summary/variants/244/summary#variant	ATM	472	N2875H	A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain		11	108218044	108218044	A	C	ENST00000278616.4	75	GRCh37				
245	https://civic.genome.wustl.edu/#/events/genes/3870/summary/variants/245/summary#variant	NF2	4771	Y177FS			22	30051593	30051594		T	ENST00000338641.4	75	GRCh37				
247	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/247/summary#variant	PDGFRA	5156	V561A			4	55141036	55141036	T	C	ENST00000257290.5	75	GRCh37				
248	https://civic.genome.wustl.edu/#/events/genes/79/summary/variants/248/summary#variant	TERT	7015	C228T			5	1295228	1295228	G	A	ENST00000310581.5	75	GRCh37				
249	https://civic.genome.wustl.edu/#/events/genes/6144/summary/variants/249/summary#variant	XRCC1	7515	R194W			19	44057574	44057574	G	A	ENST00000262887.5	75	GRCh37				
250	https://civic.genome.wustl.edu/#/events/genes/2473/summary/variants/250/summary#variant	GSTP1	2950	DELETION			11	67351066	67354131			ENST00000398606.3	75	GRCh37				
251	https://civic.genome.wustl.edu/#/events/genes/14842/summary/variants/251/summary#variant	BIRC7	79444	AMPLIFICATION			20	61867235	61871859			ENST00000217169.3	75	GRCh37				
252	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/252/summary#variant	EGFR	1956	EXON 4 DELETION			7	55214299	55214433			ENST00000275493.2	75	GRCh37				
253	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/253/summary#variant	EGFR	1956	3' UTR MUTATION														
254	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/254/summary#variant	KRAS	3845	RS61764370	Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy.		12	25360224	25360224	A	C	ENST00000311936.3	75	GRCh37				
255	https://civic.genome.wustl.edu/#/events/genes/1741/summary/variants/255/summary#variant	ERCC5	2073	5' UTR MUTATION			13	103497194	103498616			ENST00000355739.4	75	GRCh37				
256	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/256/summary#variant	KIT	3815	3' UTR MUTATION			4	55604724	55606881			ENST00000288135.5	75	GRCh37				
257	https://civic.genome.wustl.edu/#/events/genes/63/summary/variants/257/summary#variant	EZH2	2146	INTRON 6 MUTATION			7	148524359	148525831			ENST00000320356.2	75	GRCh37				
258	https://civic.genome.wustl.edu/#/events/genes/3672/summary/variants/258/summary#variant	MTHFR	4524	C677T			1	11856378	11856378	G	A	ENST00000376592.1	75	GRCh37				
259	https://civic.genome.wustl.edu/#/events/genes/2473/summary/variants/259/summary#variant	GSTP1	2950	I105V			11	67352689	67352689	A	G	ENST00000398606.3	75	GRCh37				
260	https://civic.genome.wustl.edu/#/events/genes/7451/summary/variants/260/summary#variant	ABCG2	9429	Q141K			4	89052323	89052323	G	T	ENST00000237612.3	75	GRCh37				
261	https://civic.genome.wustl.edu/#/events/genes/6144/summary/variants/261/summary#variant	XRCC1	7515	R399Q														
262	https://civic.genome.wustl.edu/#/events/genes/4244/summary/variants/262/summary#variant	ABCB1	5243	S893T (A893S)			7	87160618	87160618	A	T	ENST00000265724.3	75	GRCh37				
263	https://civic.genome.wustl.edu/#/events/genes/4244/summary/variants/263/summary#variant	ABCB1	5243	I1145I (T3435C)	rs1045642		7	87138645	87138645	A	G	ENST00000265724.3	75	GRCh37				
264	https://civic.genome.wustl.edu/#/events/genes/1736/summary/variants/264/summary#variant	ERCC2	2068	K751Q			19	45854919	45854919	T	G	ENST00000391945.4	75	GRCh37				
265	https://civic.genome.wustl.edu/#/events/genes/5971/summary/variants/265/summary#variant	TYMS	7298	5' TANDEM REPEAT									75	GRCh37				
266	https://civic.genome.wustl.edu/#/events/genes/12146/summary/variants/266/summary#variant	LRP1B	53353	EXON 1222 DELETION			2	141665446	141777671			ENST00000389484.3	75	GRCh37				
267	https://civic.genome.wustl.edu/#/events/genes/1885/summary/variants/267/summary#variant	FGFR1	2260	AMPLIFICATION	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al.). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al.). Clinical studies are currently ongoing (e.g. NCT01004224).  PMID: 26373574  PMID: 21160078		8	38268656	38325363			ENST00000425967.3	75	GRCh37				
268	https://civic.genome.wustl.edu/#/events/genes/1885/summary/variants/268/summary#variant	FGFR1	2260	EXPRESSION	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al.). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al.). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al.). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al.), HNSSC (Gke et. al.) and urothelial carcinoma (Lamont et. al.). PMID: 24771645 PMID: 26015511 PMID: 16807070 PMID: 21119661		8	38268656	38325363			ENST00000425967.3	75	GRCh37				
269	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/269/summary#variant	ROS1	6098	REARRANGEMENT	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, J Clin Oncol. 2015 Mar 20;33(9):972-4. doi: 10.1200/JCO.2014.59.8334.). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al., N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766).		6	117609463	117747018			ENST00000368508.3	75	GRCh37				
270	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/270/summary#variant	MET	4233	AMPLIFICATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37				
271	https://civic.genome.wustl.edu/#/events/genes/524/summary/variants/271/summary#variant	ATR	545	I774FS	Single A insertion or deletion in the 10 A mononucleotide run in exon 10 of ATR results in a frameshift of codon I774. In patients with endometrial cancer, this mutation has only been observed in patients with microsatellite instability.		3	142274740	142274740	A	-	ENST00000350721.4	75	GRCh37				
272	https://civic.genome.wustl.edu/#/events/genes/14/summary/variants/272/summary#variant	CDKN2A	1029	EXPRESSION	CDKN2A expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A (p16) and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered on expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO December 10, 2014 vol. 32 no. 35 3914-3916, doi: 10.1200/JCO.2014.57.9268). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.		9	21968055	21974865			ENST00000498124.1	75	GRCh37				
273	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/273/summary#variant	RET	5979	KIF5B-RET	In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., Nature Medicine 18, 378381 (2012) doi:10.1038/nm.2658)													
274	https://civic.genome.wustl.edu/#/events/genes/2747/summary/variants/274/summary#variant	HRAS	3265	G13D			11	534285	534285	C	T	ENST00000451590.1	75	GRCh37				
275	https://civic.genome.wustl.edu/#/events/genes/2747/summary/variants/275/summary#variant	HRAS	3265	MUTATION			11	533873	534289			ENST00000451590.1	75	GRCh37				
276	https://civic.genome.wustl.edu/#/events/genes/11335/summary/variants/276/summary#variant	CD274	29126	EXPRESSION			9	5450525	5470547			ENST00000381577.3	75	GRCh37				
277	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/277/summary#variant	MTOR	2475	MUTATION			1	11166592	11322564			ENST00000361445.4	75	GRCh37				
278	https://civic.genome.wustl.edu/#/events/genes/254/summary/variants/278/summary#variant	AKT2	208	EXPRESSION			19	40736224	40791302			ENST00000392038.2	75	GRCh37				
279	https://civic.genome.wustl.edu/#/events/genes/3870/summary/variants/279/summary#variant	NF2	4771	K159FS*16														
281	https://civic.genome.wustl.edu/#/events/genes/12903/summary/variants/281/summary#variant	FBXW7	55294	MUTATION			4	153245446	153332714			ENST00000281708.4	75	GRCh37				
282	https://civic.genome.wustl.edu/#/events/genes/77/summary/variants/282/summary#variant	SMAD4	4089	UNDEREXPRESSION			18	48556583	48611409			ENST00000342988.3	75	GRCh37				
283	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/283/summary#variant	MTOR	2475	H1968Y			1	11188519	11188519	G	A	ENST00000361445.4	75	GRCh37				
284	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/284/summary#variant	MTOR	2475	P2213S			1	11184580	11184580	G	A	ENST00000361445.4	75	GRCh37				
285	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/285/summary#variant	BRAF	673	AGK-BRAF			7	141250989	141255367			ENST00000355413.4	75	GRCh37	7	140434279	140494267	ENST00000288602.6
286	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/286/summary#variant	BRAF	673	PAPSS1-BRAF			4	108603171	108641608			ENST00000265174.4	75	GRCh37	7	140434279	140487384	ENST00000288602.6
287	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/287/summary#variant	BRAF	673	TRIM24-BRAF			7	138145079	138239711			ENST00000343526.4	75	GRCh37	7	140434279	140487384	ENST00000288602.6
288	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/288/summary#variant	BRAF	673	L597R			7	140453145	140453145	A	C	ENST00000288602.6	75	GRCh37				
289	https://civic.genome.wustl.edu/#/events/genes/1733/summary/variants/289/summary#variant	ERBB3	2065	OVEREXPRESSION			12	56473645	56497289			ENST00000267101.3	75	GRCh37				
290	https://civic.genome.wustl.edu/#/events/genes/3976/summary/variants/290/summary#variant	NT5E	4907	OVEREXPRESSION			6	86159809	86205496			ENST00000257770.3	75	GRCh37				
291	https://civic.genome.wustl.edu/#/events/genes/63/summary/variants/291/summary#variant	EZH2	2146	OVEREXPRESSION			7	148504477	148581370			ENST00000320356.2	75	GRCh37				
292	https://civic.genome.wustl.edu/#/events/genes/3742/summary/variants/292/summary#variant	MYD88	4615	OVEREXPRESSION			3	38179969	38184510			ENST00000417037.2	75	GRCh37				
294	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/294/summary#variant	PIK3CA	5290	P471L			3	178928226	178928226	C	T	ENST00000263967.3	75	GRCh37				
295	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/295/summary#variant	RET	5979	EXPRESSION			10	43572475	43625799			ENST00000355710.3	75	GRCh37				
296	https://civic.genome.wustl.edu/#/events/genes/4875/summary/variants/296/summary#variant	RIT1	6016	OVEREXPRESSION			1	155870065	155880706			ENST00000368322.3	75	GRCh37				
297	https://civic.genome.wustl.edu/#/events/genes/4875/summary/variants/297/summary#variant	RIT1	6016	MUTATION			1	155870065	155880706			ENST00000368322.3	75	GRCh37				
298	https://civic.genome.wustl.edu/#/events/genes/3741/summary/variants/298/summary#variant	MYCN	4613	AMPLIFICATION			2	16080686	16087129			ENST00000281043.3	75	GRCh37				
299	https://civic.genome.wustl.edu/#/events/genes/5365/summary/variants/299/summary#variant	SMO	6608	D473H			7	128849189	128849189	G	C	ENST00000249373.3	75	GRCh37				
300	https://civic.genome.wustl.edu/#/events/genes/5365/summary/variants/300/summary#variant	SMO	6608	MUTATION			7	128828713	128853386			ENST00000249373.3	75	GRCh37				
301	https://civic.genome.wustl.edu/#/events/genes/4645/summary/variants/301/summary#variant	PTCH1	5727	MUTATION			9	98205262	98270943			ENST00000331920.6	75	GRCh37				
302	https://civic.genome.wustl.edu/#/events/genes/4645/summary/variants/302/summary#variant	PTCH1	5727	LOH			9	98205262	98270943			ENST00000331920.6	75	GRCh37				
303	https://civic.genome.wustl.edu/#/events/genes/5534/summary/variants/303/summary#variant	STK11	6794	EXON 1-2 MUTATION			19	1205740	1218499			ENST00000326873.7	75	GRCh37				
304	https://civic.genome.wustl.edu/#/events/genes/5534/summary/variants/304/summary#variant	STK11	6794	UNDEREXPRESSION			19	1205740	1228428			ENST00000326873.7	75	GRCh37				
305	https://civic.genome.wustl.edu/#/events/genes/5572/summary/variants/305/summary#variant	SYK	6850	OVEREXPRESSION			9	93564069	93660831			ENST00000375754.4	75	GRCh37				
306	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/306/summary#variant	ERBB2	2064	AMPLIFICATION	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial.		17	37856333	37884915			ENST00000269571.5	75	GRCh37				
307	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/307/summary#variant	ALK	238	EML4-ALK L1152R			2	29445270	29445270	A	C	ENST00000389048.3	75	GRCh37				
308	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/308/summary#variant	ALK	238	EML4-ALK G1269A			2	29432682	29432682	C	G	ENST00000389048.3	75	GRCh37				
309	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/309/summary#variant	EGFR	1956	AUTOCRINE ACTIVATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37				
310	https://civic.genome.wustl.edu/#/events/genes/1734/summary/variants/310/summary#variant	ERBB4	2066	MUTATION	ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib (Arteaga CL, Cancer Cell. 2014 Mar 17;25(3):282-303. doi: 10.1016/j.ccr.2014.02.025.).		2	212295697	212578308			ENST00000342788.4	75	GRCh37				
311	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/311/summary#variant	PIK3CA	5290	MUTATION			3	178866311	178957881			ENST00000263967.3	75	GRCh37				
312	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/312/summary#variant	EGFR	1956	VIII	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga CL, Engelman JA; Cancer Cell. 2014 Mar 17;25(3):282-303. doi: 10.1016/j.ccr.2014.02.025.)		7	55087058	55223523			ENST00000275493.2	75	GRCh37				
313	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/313/summary#variant	PTEN	5728	EXPRESSION			10	89622870	89731687			ENST00000371953.3	75	GRCh37				
314	https://civic.genome.wustl.edu/#/events/genes/2593/summary/variants/314/summary#variant	NRG1	3084	EXPRESSION			8	31497942	32622294			ENST00000523534.1	75	GRCh37				
315	https://civic.genome.wustl.edu/#/events/genes/389/summary/variants/315/summary#variant	AREG	374	EXPRESSION			4	75310851	75320726			ENST00000395748.3	75	GRCh37				
316	https://civic.genome.wustl.edu/#/events/genes/5742/summary/variants/316/summary#variant	TGFA	7039	EXPRESSION			2	70674412	70781147			ENST00000295400.6	75	GRCh37				
317	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/317/summary#variant	EGFR	1956	G724S			7	55241722	55241722	G	A	ENST00000275493.2	75	GRCh37				
318	https://civic.genome.wustl.edu/#/events/genes/1737/summary/variants/318/summary#variant	EREG	2069	EXPRESSION			4	75230860	75254468			ENST00000244869.2	75	GRCh37				
319	https://civic.genome.wustl.edu/#/events/genes/1627/summary/variants/319/summary#variant	EFNA2	1943	EXPRESSION			19	1286153	1301430			ENST00000215368.2	75	GRCh37				
320	https://civic.genome.wustl.edu/#/events/genes/4532/summary/variants/320/summary#variant	MAPK1	5594	E322K			2	22127164	22127164	C	T	ENST00000215832.6	75	GRCh37				
321	https://civic.genome.wustl.edu/#/events/genes/4532/summary/variants/321/summary#variant	MAPK1	5594	AMPLIFICATION			22	22108789	22221919			ENST00000215832.6	75	GRCh37				
322	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/322/summary#variant	KRAS	3845	A146V			12	25378561	25378561	G	A	ENST00000256078.4	75	GRCh37				
323	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/323/summary#variant	MET	4233	MUTATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37				
324	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/324/summary#variant	MET	4233	EXON 14 SKIPPING MUTATION	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports. Larger studies are needed but may prove therapeutically beneficial for NSCLC patients with exon 14 skipping mutations.		7	116411903	116412043			ENST00000318493.6	75	GRCh37				
325	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/325/summary#variant	FGFR3	2261	EXPRESSION			4	1795039	1810599			ENST00000440486.2	75	GRCh37				
326	https://civic.genome.wustl.edu/#/events/genes/9705/summary/variants/326/summary#variant	CBLC	23624	EXPRESSION			19	45281126	45303891			ENST00000270279.3	75	GRCh37				
327	https://civic.genome.wustl.edu/#/events/genes/4692/summary/variants/327/summary#variant	PTPRD	5789	MUTATION			9	8314246	10033790			ENST00000381196.4	75	GRCh37				
328	https://civic.genome.wustl.edu/#/events/genes/1428/summary/variants/328/summary#variant	DEFA1	1667	EXPRESSION			8	6835172	6837602			ENST00000382692.2	75	GRCh37				
329	https://civic.genome.wustl.edu/#/events/genes/1735/summary/variants/329/summary#variant	ERCC1	2067	EXPRESSION			19	45916692	45926824			ENST00000013807.5	75	GRCh37				
330	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/330/summary#variant	NOTCH1	4851	AMPLIFICATION			9	139388896	139440314			ENST00000277541.6	75	GRCh37				
331	https://civic.genome.wustl.edu/#/events/genes/6104/summary/variants/331/summary#variant	WEE1	7465	POLYMORPHISM														
332	https://civic.genome.wustl.edu/#/events/genes/1950/summary/variants/332/summary#variant	FNTB	2342	POLYMORPHISM														
333	https://civic.genome.wustl.edu/#/events/genes/8878/summary/variants/333/summary#variant	PTPRT	11122	PROMOTER HYPERMETHYLATION														
334	https://civic.genome.wustl.edu/#/events/genes/6071/summary/variants/334/summary#variant	VEGFA	7422	UNDEREXPRESSION			6	43738444	43752346			ENST00000372055.4	75	GRCh37				
335	https://civic.genome.wustl.edu/#/events/genes/1510/summary/variants/335/summary#variant	DNMT1	1786	EXPRESSION			19	10244022	10305811			ENST00000340748.4	75	GRCh37				
336	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/336/summary#variant	KRAS	3845	MUTATION			12	25362365	25403737			ENST00000256078.4	75	GRCh37				
337	https://civic.genome.wustl.edu/#/events/genes/10573/summary/variants/337/summary#variant	PDCD4	27250	EXPRESSION	A new study, a retrospective analysis of 77 patients, has implicated PDCD4 expression in the sensitivity to paclitaxel. However, this finding came from a large proteome screen and has not yet been replicated in independent patient sets.		10	112631596	112659763			ENST00000393104.2	75	GRCh37				
338	https://civic.genome.wustl.edu/#/events/genes/34/summary/variants/338/summary#variant	MGMT	4255	POLYMORPHISM														
339	https://civic.genome.wustl.edu/#/events/genes/5737/summary/variants/339/summary#variant	TFF3	7033	EXPRESSION			21	43731777	43735761			ENST00000518498.1	75	GRCh37				
340	https://civic.genome.wustl.edu/#/events/genes/9171/summary/variants/340/summary#variant	DKK1	22943	NUCLEAR EXPRESSION			10	54074056	54077417			ENST00000373970.3	75	GRCh37				
341	https://civic.genome.wustl.edu/#/events/genes/855/summary/variants/341/summary#variant	CD44	960	ISOFORM EXPRESSION			11	35160728	35251574			ENST00000428726.2	75	GRCh37				
342	https://civic.genome.wustl.edu/#/events/genes/1634/summary/variants/342/summary#variant	EGF	1950	EXPRESSION			4	110834047	110933422			ENST00000265171.5	75	GRCh37				
343	https://civic.genome.wustl.edu/#/events/genes/3465/summary/variants/343/summary#variant	MDM2	4193	EXPRESSION			12	69201956	69239214			ENST00000462284.1	75	GRCh37				
344	https://civic.genome.wustl.edu/#/events/genes/2657/summary/variants/344/summary#variant	HMOX1	3162	EXPRESSION			22	35776828	35790207			ENST00000216117.8	75	GRCh37				
345	https://civic.genome.wustl.edu/#/events/genes/7041/summary/variants/345/summary#variant	SPHK1	8877	OVEREXPRESSION			17	74380731	74383936			ENST00000323374.4	75	GRCh37				
346	https://civic.genome.wustl.edu/#/events/genes/761/summary/variants/346/summary#variant	CASP8	841	EXPRESSION			2	202122759	202152434			ENST00000358485.4	75	GRCh37				
347	https://civic.genome.wustl.edu/#/events/genes/5971/summary/variants/347/summary#variant	TYMS	7298	EXPRESSION			18	657604	673578			ENST00000323274.10	75	GRCh37				
348	https://civic.genome.wustl.edu/#/events/genes/13276/summary/variants/348/summary#variant	PBK	55872	OVEREXPRESSION			8	27667137	27695612			ENST00000301905.4	75	GRCh37				
349	https://civic.genome.wustl.edu/#/events/genes/78/summary/variants/349/summary#variant	SMARCA4	6597	UNDEREXPRESSION			19	11071598	11172958			ENST00000358026.2	75	GRCh37				
350	https://civic.genome.wustl.edu/#/events/genes/10024/summary/variants/350/summary#variant	SETBP1	26040	EXON 4 MUTATION			18	42531877	42531918			ENST00000282030.5	75	GRCh37				
351	https://civic.genome.wustl.edu/#/events/genes/10024/summary/variants/351/summary#variant	SETBP1	26040	G870S			18	42531913	42531913	G	A	ENST00000282030.5	75	GRCh37				
352	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/352/summary#variant	ALK	238	EML4-ALK C1156YL1198F			2	29443625	29445258			ENST00000389048.3	75	GRCh37				
353	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/353/summary#variant	BRCA1	672	LOSS			17	41196312	41277387			ENST00000357654.3	75	GRCh37				
354	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/354/summary#variant	EGFR	1956	EXPRESSION			7	55086794	55279321			ENST00000275493.2	75	GRCh37				
355	https://civic.genome.wustl.edu/#/events/genes/913/summary/variants/355/summary#variant	CDKN1A	1026	EXPRESSION			6	36646487	36655108			ENST00000405375.1	75	GRCh37				
356	https://civic.genome.wustl.edu/#/events/genes/259/summary/variants/356/summary#variant	ALCAM	214	EXPRESSION			3	105085753	105295744			ENST00000306107.5	75	GRCh37				
357	https://civic.genome.wustl.edu/#/events/genes/3255/summary/variants/357/summary#variant	STMN1	3925	EXPRESSION			1	26211931	26232957			ENST00000426559.2	75	GRCh37				
358	https://civic.genome.wustl.edu/#/events/genes/12121/summary/variants/358/summary#variant	RSF1	51773	AMPLIFICATION			11	77371041	77532063			ENST00000308488.6	75	GRCh37				
359	https://civic.genome.wustl.edu/#/events/genes/67/summary/variants/359/summary#variant	AR	367	OVEREXPRESSION			X	66764465	66950461			ENST00000374690.3	75	GRCh37				
360	https://civic.genome.wustl.edu/#/events/genes/914/summary/variants/360/summary#variant	CDKN1B	1027	CYTOPLASMIC MISLOCALIZATION			12	12870058	12875305			ENST00000228872.4	75	GRCh37				
361	https://civic.genome.wustl.edu/#/events/genes/1733/summary/variants/361/summary#variant	ERBB3	2065	EXPRESSION			12	56473645	56497289			ENST00000267101.3	75	GRCh37				
362	https://civic.genome.wustl.edu/#/events/genes/67/summary/variants/362/summary#variant	AR	367	SPLICE VARIANT 7			X	66764662	66915917			ENST00000504326.1	75	GRCh37				
363	https://civic.genome.wustl.edu/#/events/genes/6023/summary/variants/363/summary#variant	UGT1A	7361	EXPRESSION			2	234526291	234681956			ENST00000373450.4	75	GRCh37				
364	https://civic.genome.wustl.edu/#/events/genes/1734/summary/variants/364/summary#variant	ERBB4	2066	NUCLEAR TRANSLOCATION			2	212240446	213403565			ENST00000342788.4	75	GRCh37				
365	https://civic.genome.wustl.edu/#/events/genes/1734/summary/variants/365/summary#variant	ERBB4	2066	EXPRESSION			2	212240446	213403565			ENST00000342788.4	75	GRCh37				
366	https://civic.genome.wustl.edu/#/events/genes/16872/summary/variants/366/summary#variant	SLFN11	91607	EXPRESSION			17	33677324	33700639			ENST00000394566.1	75	GRCh37				
367	https://civic.genome.wustl.edu/#/events/genes/4753/summary/variants/367/summary#variant	RAC1	5879	P29S			7	6426892	6426892	C	T	ENST00000356142.4	75	GRCh37				
368	https://civic.genome.wustl.edu/#/events/genes/355/summary/variants/368/summary#variant	BIRC5	332	NUCLEAR EXPRESSION			17	76210267	76221717			ENST00000301633.4	75	GRCh37				
369	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/369/summary#variant	TP53	7157	WILD TYPE			17	7571720	7590856			ENST00000269305.4	75	GRCh37				
370	https://civic.genome.wustl.edu/#/events/genes/3586/summary/variants/370/summary#variant	MRE11A	4361	LOSS			11	94152895	94227074			ENST00000323929.3	75	GRCh37				
371	https://civic.genome.wustl.edu/#/events/genes/5845/summary/variants/371/summary#variant	TOP1	7150	AMPLIFICATION			20	39657458	39753127			ENST00000361337.2	75	GRCh37				
372	https://civic.genome.wustl.edu/#/events/genes/914/summary/variants/372/summary#variant	CDKN1B	1027	EXPRESSION			12	12870058	12875305			ENST00000228872.4	75	GRCh37				
373	https://civic.genome.wustl.edu/#/events/genes/8407/summary/variants/373/summary#variant	AGR2	10551	EXPRESSION			7	16831435	16844704			ENST00000419304.2	75	GRCh37				
374	https://civic.genome.wustl.edu/#/events/genes/17016/summary/variants/374/summary#variant	NAPRT	93100	PROMOTER HYPERMETHYLATION														
375	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/375/summary#variant	EGFR	1956	EXON 18 OVEREXPRESSION			7	55237999	55238735			ENST00000344576.2	75	GRCh37				
376	https://civic.genome.wustl.edu/#/events/genes/5649/summary/variants/376/summary#variant	ZEB1	6935	EXPRESSION			10	31608101	31818741			ENST00000361642.5	75	GRCh37				
377	https://civic.genome.wustl.edu/#/events/genes/5777/summary/variants/377/summary#variant	TIMP1	7076	OVEREXPRESSION			X	47441712	47446188			ENST00000218388.4	75	GRCh37				
378	https://civic.genome.wustl.edu/#/events/genes/8908/summary/variants/378/summary#variant	PTP4A3	11156	OVEREXPRESSION			8	142402093	142441394			ENST00000521578.1	75	GRCh37				
379	https://civic.genome.wustl.edu/#/events/genes/5971/summary/variants/379/summary#variant	TYMS	7298	AMPLIFICATION			18	657604	673578			ENST00000323274.10	75	GRCh37				
380	https://civic.genome.wustl.edu/#/events/genes/2899/summary/variants/380/summary#variant	IGF1R	3480	EXPRESSION			15	99192200	99507759			ENST00000268035.6	75	GRCh37				
381	https://civic.genome.wustl.edu/#/events/genes/1721/summary/variants/381/summary#variant	EPHB4	2050	EXPRESSION			7	100400187	100425121			ENST00000358173.3	75	GRCh37				
382	https://civic.genome.wustl.edu/#/events/genes/5971/summary/variants/382/summary#variant	TYMS	7298	UNDEREXPRESSION			18	657604	673578			ENST00000323274.10	75	GRCh37				
383	https://civic.genome.wustl.edu/#/events/genes/5848/summary/variants/383/summary#variant	TOP2A	7153	EXPRESSION			17	38544768	38574202			ENST00000423485.1	75	GRCh37				
384	https://civic.genome.wustl.edu/#/events/genes/5845/summary/variants/384/summary#variant	TOP1	7150	EXPRESSION			20	39657458	39753127			ENST00000361337.2	75	GRCh37				
385	https://civic.genome.wustl.edu/#/events/genes/4503/summary/variants/385/summary#variant	PRKAA2	5563	T172 PHOSPHORYLATION			1	57159476	57159478			ENST00000371244.4	75	GRCh37				
386	https://civic.genome.wustl.edu/#/events/genes/2778/summary/variants/386/summary#variant	HSPA5	3309	EXPRESSION			9	127997132	128003609			ENST00000324460.6	75	GRCh37				
387	https://civic.genome.wustl.edu/#/events/genes/1655/summary/variants/387/summary#variant	EIF4EBP1	1978	PHOSPHORYLATION			8	37888200	37914663			ENST00000338825.4	75	GRCh37				
388	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/388/summary#variant	KIT	3815	MUTATION			4	55524085	55606881			ENST00000288135.5	75	GRCh37				
389	https://civic.genome.wustl.edu/#/events/genes/8262/summary/variants/389/summary#variant	TUBB3	10381	EXPRESSION			16	89989687	90002505			ENST00000315491.7	75	GRCh37				
390	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/390/summary#variant	EGFR	1956	Y1092 PHOSPHORYLATION			7	55272951	55272953			ENST00000275493.2	75	GRCh37				
391	https://civic.genome.wustl.edu/#/events/genes/2899/summary/variants/391/summary#variant	IGF1R	3480	NUCLEAR EXPRESSION			15	99192200	99507759			ENST00000268035.6	75	GRCh37				
392	https://civic.genome.wustl.edu/#/events/genes/7009/summary/variants/392/summary#variant	CFLAR	8837	EXPRESSION			2	201980827	202041410			ENST00000309955.3	75	GRCh37				
393	https://civic.genome.wustl.edu/#/events/genes/7014/summary/variants/393/summary#variant	PROM1	8842	EXPRESSION			4	15969857	16085324			ENST00000510224.1	75	GRCh37				
394	https://civic.genome.wustl.edu/#/events/genes/11587/summary/variants/394/summary#variant	FOXP3	50943	EXPRESSION			X	49106897	49121288			ENST00000376207.4	75	GRCh37				
395	https://civic.genome.wustl.edu/#/events/genes/5013/summary/variants/395/summary#variant	RPS6	6194	PHOSPHORYLATION			9	19376309	19376323			ENST00000380394.4	75	GRCh37				
396	https://civic.genome.wustl.edu/#/events/genes/3090/summary/variants/396/summary#variant	JAK1	3716	OVEREXPRESSION			1	65298912	65432187			ENST00000342505.4	75	GRCh37				
397	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/397/summary#variant	BRCA1	672	EXPRESSION			17	41196312	41277387			ENST00000357654.3	75	GRCh37				
398	https://civic.genome.wustl.edu/#/events/genes/1567/summary/variants/398/summary#variant	DUSP6	1848	EXPRESSION			12	89741009	89747048			ENST00000279488.7	75	GRCh37				
399	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/399/summary#variant	BRAF	673	MUTATION			7	140453136	140481403			ENST00000288602.6	75	GRCh37				
400	https://civic.genome.wustl.edu/#/events/genes/2784/summary/variants/400/summary#variant	HSPB1	3315	EXPRESSION			7	75931861	75933612			ENST00000248553.6	75	GRCh37				
401	https://civic.genome.wustl.edu/#/events/genes/1463/summary/variants/401/summary#variant	NQO1	1728	EXPRESSION			16	69743304	69760854			ENST00000320623.5	75	GRCh37				
402	https://civic.genome.wustl.edu/#/events/genes/1463/summary/variants/402/summary#variant	NQO1	1728	P187S			16	69745145	69745145	G	A	ENST00000320623.5	75	GRCh37				
403	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/403/summary#variant	BRCA1	672	UNDEREXPRESSION			17	41196312	41277387			ENST00000357654.3	75	GRCh37				
404	https://civic.genome.wustl.edu/#/events/genes/4244/summary/variants/404/summary#variant	ABCB1	5243	EXPRESSION			7	87133175	87342564			ENST00000265724.3	75	GRCh37				
405	https://civic.genome.wustl.edu/#/events/genes/6329/summary/variants/405/summary#variant	CXCR4	7852	EXPRESSION			2	136871919	136873813			ENST00000409817.1	75	GRCh37				
406	https://civic.genome.wustl.edu/#/events/genes/11261/summary/variants/406/summary#variant	MAGEH1	28986	EXPRESSION			X	55478538	55479998			ENST00000342972.1	75	GRCh37				
407	https://civic.genome.wustl.edu/#/events/genes/6906/summary/variants/407/summary#variant	ABCC3	8714	AMPLIFICATION			17	48712218	48769613			ENST00000285238.8	75	GRCh37				
408	https://civic.genome.wustl.edu/#/events/genes/16656/summary/variants/408/summary#variant	ABCC10	89845	EXPRESSION			6	43395292	43418168			ENST00000372530.4	75	GRCh37				
409	https://civic.genome.wustl.edu/#/events/genes/446/summary/variants/409/summary#variant	ASNS	440	AMPLIFICATION			7	97481430	97501854			ENST00000175506.4	75	GRCh37				
410	https://civic.genome.wustl.edu/#/events/genes/927/summary/variants/410/summary#variant	CDX2	1045	EXPRESSION			13	28536274	28545276			ENST00000381020.7	75	GRCh37				
411	https://civic.genome.wustl.edu/#/events/genes/5516/summary/variants/411/summary#variant	STAT3	6774	SH2 DOMAIN MUTATION			17	40465342	40475372			ENST00000264657.5	75	GRCh37				
412	https://civic.genome.wustl.edu/#/events/genes/4419/summary/variants/412/summary#variant	POU5F1	5460	EXPRESSION			6	31132120	31138470			ENST00000259915.8	75	GRCh37				
413	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/413/summary#variant	ERBB2	2064	KINASE DOMAIN MUTATION			17	37879863	37882870			ENST00000269571.5	75	GRCh37				
414	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/414/summary#variant	ERBB2	2064	M774INSAYVM	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.		17	37880993	37880994		GCTTACGTGATG	ENST00000269571.5	75	GRCh37				
415	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/415/summary#variant	EGFR	1956	C797S			7	55249091	55249091	T	A	ENST00000275493.2	75	GRCh37				
416	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/416/summary#variant	ERBB2	2064	SERUM LEVELS			17	37856333	37884915			ENST00000269571.5	75	GRCh37				
417	https://civic.genome.wustl.edu/#/events/genes/5761/summary/variants/417/summary#variant	THBS2	7058	UNDEREXPRESSION			6	169615875	169654139			ENST00000366787.3	75	GRCh37				
419	https://civic.genome.wustl.edu/#/events/genes/3983/summary/variants/419/summary#variant	NTRK1	4914	3' FUSION			1	156844175	156851434			ENST00000524377.1	75	GRCh37				
420	https://civic.genome.wustl.edu/#/events/genes/26/summary/variants/420/summary#variant	IDH1	3417	R132H	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113112	209113112	C	T	ENST00000415913.1	75	GRCh37				
421	https://civic.genome.wustl.edu/#/events/genes/79/summary/variants/421/summary#variant	TERT	7015	RS2736100			5	1286516	1286516	C	A	ENST00000310581.5	75	GRCh37				
422	https://civic.genome.wustl.edu/#/events/genes/8553/summary/variants/422/summary#variant	STAG2	10735	UNDEREXPRESSION			X	123095568	123236506			ENST00000371157.3	75	GRCh37				
423	https://civic.genome.wustl.edu/#/events/genes/2622/summary/variants/423/summary#variant	HLA-DRA	3122	EXPRESSION			6	32407619	32412823			ENST00000395388.2	75	GRCh37				
424	https://civic.genome.wustl.edu/#/events/genes/3742/summary/variants/424/summary#variant	MYD88	4615	L265P			3	38182641	38182641	T	C	ENST00000396334.3	75	GRCh37				
425	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/425/summary#variant	KRAS	3845	G12V			12	25398284	25398284	C	A	ENST00000256078.4	75	GRCh37				
426	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/426/summary#variant	BRAF	673	WILD TYPE			7	140434279	140624564			ENST00000288602.6	75	GRCh37				
427	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/427/summary#variant	NRAS	4893	Q61K			1	115256530	115256530	G	T	ENST00000369535.4	75	GRCh37				
428	https://civic.genome.wustl.edu/#/events/genes/3586/summary/variants/428/summary#variant	MRE11A	4361	FRAMESHIFT MUTATION			11	94152895	94227074			ENST00000323929.3	75	GRCh37				
429	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/429/summary#variant	KIT	3815	EXPRESSION			4	55524085	55606881			ENST00000288135.5	75	GRCh37				
430	https://civic.genome.wustl.edu/#/events/genes/3755/summary/variants/430/summary#variant	MYH11	4629	CBFB-MYH11														
431	https://civic.genome.wustl.edu/#/events/genes/776/summary/variants/431/summary#variant	CBFB	865	CBFB-MYH11														
432	https://civic.genome.wustl.edu/#/events/genes/3537/summary/variants/432/summary#variant	KMT2A	4297	MLL-MLLT3														
433	https://civic.genome.wustl.edu/#/events/genes/2596/summary/variants/433/summary#variant	HIF1A	3091	3' UTR Polymorphism														
434	https://civic.genome.wustl.edu/#/events/genes/2596/summary/variants/434/summary#variant	HIF1A	3091	OVEREXPRESSION			14	62162258	62214976			ENST00000394997.1	75	GRCh37				
435	https://civic.genome.wustl.edu/#/events/genes/1705/summary/variants/435/summary#variant	EPAS1	2034	OVEREXPRESSION			2	46524541	46613836			ENST00000263734.3	75	GRCh37				
436	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/436/summary#variant	VHL	7428	LOSS			3	10182692	10193904			ENST00000256474.2	75	GRCh37				
437	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/437/summary#variant	FLT3	2322	D835			13	28592642	28592642	C	A	ENST00000241453.7	75	GRCh37				
438	https://civic.genome.wustl.edu/#/events/genes/4616/summary/variants/438/summary#variant	PSMB8	5696	NUCLEAR EXPRESSION			6	32808494	32812480			ENST00000374881.2	75	GRCh37				
439	https://civic.genome.wustl.edu/#/events/genes/13276/summary/variants/439/summary#variant	PBK	55872	NUCLEAR EXPRESSION			8	27667137	27695612			ENST00000301905.4	75	GRCh37				
440	https://civic.genome.wustl.edu/#/events/genes/7297/summary/variants/440/summary#variant	PTTG1	9232	OVEREXPRESSION			5	159848829	159855748			ENST00000352433.5	75	GRCh37				
441	https://civic.genome.wustl.edu/#/events/genes/3274/summary/variants/441/summary#variant	LEPR	3953	UNDEREXPRESSION			1	65886335	66107242			ENST00000349533.6	75	GRCh37				
442	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/442/summary#variant	EGFR	1956	MUTATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37				
443	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/443/summary#variant	EGFR	1956	G465R			7	55227926	55227926	G	A	ENST00000275493.2	75	GRCh37				
444	https://civic.genome.wustl.edu/#/events/genes/3852/summary/variants/444/summary#variant	NEDD9	4739	EXPRESSION			6	11185051	11382581			ENST00000504387.1	75	GRCh37				
445	https://civic.genome.wustl.edu/#/events/genes/1763/summary/variants/445/summary#variant	ETS2	2114	RS461155A>G														
446	https://civic.genome.wustl.edu/#/events/genes/3215/summary/variants/446/summary#variant	KRT18	3875	UNDEREXPRESSION			12	53342655	53346684			ENST00000388837.2	75	GRCh37				
447	https://civic.genome.wustl.edu/#/events/genes/1883/summary/variants/447/summary#variant	FGF13	2258	CYTOPLASMIC EXPRESSION			X	137715011	138286269			ENST00000370603.3	75	GRCh37				
448	https://civic.genome.wustl.edu/#/events/genes/5500/summary/variants/448/summary#variant	SSX1	6756	SS18-SSX1		SYT-SSX fusions												
449	https://civic.genome.wustl.edu/#/events/genes/5501/summary/variants/449/summary#variant	SSX2	6757	SS18-SSX2		SYT-SSX fusions												
450	https://civic.genome.wustl.edu/#/events/genes/5503/summary/variants/450/summary#variant	SSX4	6759	SS18-SSX4		SYT-SSX fusions	18	23612363	23670589			ENST00000415083.2	75	GRCh37	X	48261524	48265521	ENST00000376884.2
451	https://civic.genome.wustl.edu/#/events/genes/4244/summary/variants/451/summary#variant	ABCB1	5243	S893A/T	Refer to http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2032582   or   https://www.pharmgkb.org/rsid/rs2032582   for more information.		7	87160618	87160618	A	C	ENST00000265724.3	75	GRCh37				
453	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/453/summary#variant	EGFR	1956	S492R			7	55228009	55228009	C	A	ENST00000275493.2	75	GRCh37				
454	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/454/summary#variant	EGFR	1956	R451C			7	55227884	55227884	C	T	ENST00000275493.2	75	GRCh37				
455	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/455/summary#variant	EGFR	1956	K467T			7	55227933	55227933	A	C	ENST0000275493.2	75	GRCh37				
456	https://civic.genome.wustl.edu/#/events/genes/1842/summary/variants/456/summary#variant	FCGR2A	2212	H167R			1	161479745	161479745	A	G	ENST00000271450.6	75	GRCh37				
457	https://civic.genome.wustl.edu/#/events/genes/1844/summary/variants/457/summary#variant	FCGR3A	2214	F212V	rs396991		1	161514542	161514542	A	C	ENST00000367969.3	75	GRCh37				
458	https://civic.genome.wustl.edu/#/events/genes/1843/summary/variants/458/summary#variant	FCGR2B	2213	I232T	rs1050501		1	161674008	161674008	T	C			GRCh38				
460	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/460/summary#variant	EGFR	1956	P753S			7	55242487	55242487	C	T	ENST00000275493.2	75	GRCh37				
461	https://civic.genome.wustl.edu/#/events/genes/39/summary/variants/461/summary#variant	PML	5371	B2 DOMAIN MUTATION	The B2 domain in PML is the binding site for ATRA. Point mutations in this region have been associated with ATRA resistance in patients with APL.	PML-RARa B2 Domain	15	74315213	74315219			ENST00000268058.3	75	GRCh37				
462	https://civic.genome.wustl.edu/#/events/genes/39/summary/variants/462/summary#variant	PML	5371	A216V	A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	PML-RARa B2 Domain	15	74315213	74315213	C	T	ENST00000268058.3	75	GRCh37				
463	https://civic.genome.wustl.edu/#/events/genes/39/summary/variants/463/summary#variant	PML	5371	L218P	L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	PML-RARa B2 Domain	15	74315219	74315219	T	C	ENST00000268058.3	75	GRCh37				
464	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/464/summary#variant	MET	4233	EXON 14 MUTATION + AMPLIFICATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37				
465	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/465/summary#variant	ROS1	6098	CD74-ROS1 G2032R			6	117638347	117638347	C	T	ENST00000368508.3	75	GRCh37				
466	https://civic.genome.wustl.edu/#/events/genes/1885/summary/variants/466/summary#variant	FGFR1	2260	ZNF198-FGFR1														
467	https://civic.genome.wustl.edu/#/events/genes/3153/summary/variants/467/summary#variant	KDR	3791	A1065T			4	55955969	55955969	C	T	ENST00000263923.4	75	GRCh37				
468	https://civic.genome.wustl.edu/#/events/genes/3153/summary/variants/468/summary#variant	KDR	3791	D717V			4	55968180	55968180	T	A	ENST00000263923.4	75	GRCh37				
469	https://civic.genome.wustl.edu/#/events/genes/47/summary/variants/469/summary#variant	TSC2	7249	Q1178*			16	2130300	2130300	C	T	ENST00000219476.3	75	GRCh37				
470	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/470/summary#variant	MTOR	2475	F2108L			1	11187094	11187094	G	T	ENST00000361445.4	75	GRCh37				
471	https://civic.genome.wustl.edu/#/events/genes/4765/summary/variants/471/summary#variant	RAD51D	5892	R186*			17	35106406	35106406	C	T			GRCh38				
472	https://civic.genome.wustl.edu/#/events/genes/7024/summary/variants/472/summary#variant	ALDH1A2	8854	EXPRESSION			15	58245622	58358616			ENST00000249750.4	75	GRCh37				
473	https://civic.genome.wustl.edu/#/events/genes/7024/summary/variants/473/summary#variant	ALDH1A2	8854	UNDEREXPRESSION			15	58245622	58358616			ENST00000249750.4	75	GRCh37				
474	https://civic.genome.wustl.edu/#/events/genes/13948/summary/variants/474/summary#variant	KIAA1524	57650	EXPRESSION			3	108268716	108308299			ENST00000295746.8	75	GRCh37				
475	https://civic.genome.wustl.edu/#/events/genes/13948/summary/variants/475/summary#variant	KIAA1524	57650	UNDEREXPRESSION			3	108268716	108308299			ENST00000295746.8	75	GRCh37				
476	https://civic.genome.wustl.edu/#/events/genes/24938/summary/variants/476/summary#variant	MIR218-1	407000	MIR-218 EXPRESSION														
477	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/477/summary#variant	BRCA1	672	P968FS			17	41244645	41244646	-	AG	ENST00000471181.2	75	GRCh37				
479	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/479/summary#variant	KRAS	3845	Q22*			12	25398255	25398255	G	A	ENST00000256078.4	75	GRCh37				
480	https://civic.genome.wustl.edu/#/events/genes/18/summary/variants/480/summary#variant	DNMT3A	1788	P904L			2	25457176	25457176	G	A	ENST00000264709.3	75	GRCh37				
481	https://civic.genome.wustl.edu/#/events/genes/13005/summary/variants/481/summary#variant	DDX43	55510	OVEREXPRESSION			6	74104471	74127292			ENST00000370336.4	75	GRCh37				
482	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/482/summary#variant	KIT	3815	RS3733542														
483	https://civic.genome.wustl.edu/#/events/genes/11322/summary/variants/483/summary#variant	TBK1	29110	OVEREXPRESSION														
484	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/484/summary#variant	KRAS	3845	WILD TYPE														
485	https://civic.genome.wustl.edu/#/events/genes/5534/summary/variants/485/summary#variant	STK11	6794	LOSS														
486	https://civic.genome.wustl.edu/#/events/genes/16394/summary/variants/486/summary#variant	HAVCR2	84868	OVEREXPRESSION														
487	https://civic.genome.wustl.edu/#/events/genes/3549/summary/variants/487/summary#variant	MMP2	4313	SERUM LEVELS														
488	https://civic.genome.wustl.edu/#/events/genes/3553/summary/variants/488/summary#variant	MMP9	4318	SERUM LEVELS														
489	https://civic.genome.wustl.edu/#/events/genes/8338/summary/variants/489/summary#variant	FST	10468	SERUM LEVELS														
490	https://civic.genome.wustl.edu/#/events/genes/8614/summary/variants/490/summary#variant	HSPH1	10808	NUCLEAR EXPRESSION														
491	https://civic.genome.wustl.edu/#/events/genes/8614/summary/variants/491/summary#variant	HSPH1	10808	T17 DELETION														
492	https://civic.genome.wustl.edu/#/events/genes/26599/summary/variants/492/summary#variant	ECSCR	641700	EXPRESSION														
493	https://civic.genome.wustl.edu/#/events/genes/12367/summary/variants/493/summary#variant	ROBO4	54538	EXPRESSION														
494	https://civic.genome.wustl.edu/#/events/genes/4286/summary/variants/494/summary#variant	PIM1	5292	NUCLEAR EXPRESSION														
495	https://civic.genome.wustl.edu/#/events/genes/3465/summary/variants/495/summary#variant	MDM2	4193	SNP309														
496	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/496/summary#variant	ERBB2	2064	L866M	This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.		17	37881404	37881404	C	A	ENST00000269571.5	75	GRCh37				
497	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/497/summary#variant	ERBB2	2064	S310F			17	37868208	37868208	C	T	ENST00000269571.5	75	GRCh37				
498	https://civic.genome.wustl.edu/#/events/genes/24938/summary/variants/498/summary#variant	MIR218-1	407000	UNDEREXPRESSION														
499	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/499/summary#variant	ALK	238	ALK FUSIONS														
500	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/500/summary#variant	ALK	238	EML4-ALK E20;A20														
501	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/501/summary#variant	ALK	238	EML4-ALK E2;A20														
502	https://civic.genome.wustl.edu/#/events/genes/3153/summary/variants/502/summary#variant	KDR	3791	R961W														
503	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/503/summary#variant	ALK	238	EML4-ALK E6;A20														
504	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/504/summary#variant	TP53	7157	P47S														
505	https://civic.genome.wustl.edu/#/events/genes/2317/summary/variants/505/summary#variant	GNAQ	2776	MUTATION														
506	https://civic.genome.wustl.edu/#/events/genes/2308/summary/variants/506/summary#variant	GNA11	2767	MUTATION														
507	https://civic.genome.wustl.edu/#/events/genes/2317/summary/variants/507/summary#variant	GNAQ	2776	EXON 5 MUTATION														
508	https://civic.genome.wustl.edu/#/events/genes/4371/summary/variants/508/summary#variant	PMS2	5395	MUTATION														
509	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/509/summary#variant	KIT	3815	EXON 9 MUTATION														
510	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/510/summary#variant	PTEN	5728	MUTATION														
511	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/511/summary#variant	FGFR2	2263	MUTATION														
512	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/512/summary#variant	ALK	238	MUTATION														
513	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/513/summary#variant	ALK	238	NPM-ALK														
514	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/514/summary#variant	ALK	238	RANBP2-ALK														
515	https://civic.genome.wustl.edu/#/events/genes/1885/summary/variants/515/summary#variant	FGFR1	2260	N546K														
516	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/516/summary#variant	ROS1	6098	CD74-ROS1 L2026M														
517	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/517/summary#variant	ROS1	6098	CD74-ROS1 L2155S														
518	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/518/summary#variant	ROS1	6098	CD74-ROS1 G2101A														
519	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/519/summary#variant	FLT3	2322	MUTATION														
520	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/520/summary#variant	ALK	238	CLTC-ALK														
521	https://civic.genome.wustl.edu/#/events/genes/48/summary/variants/521/summary#variant	U2AF1	7307	MUTATION														
522	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/522/summary#variant	BRAF	673	L485-P490 IN-FRAME DELETION														
523	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/523/summary#variant	ALK	238	ARG1275GLN														
